undamentalytics Newsletter
Sign in

Verrica Pharmaceuticals Inc. income statement

In fiscal 2025, Verrica Pharmaceuticals Inc. reported revenue of $35.6m, up 370.2% on the year before, operating income of −$12.2m (a -34.2% margin) and net income of −$17.9m, or −$1.68 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue129583630
Cost of revenue——13——
Gross profit——55——
Research and development16122012915
Selling, general and administrative—1747593538
General and administrative27—————
Operating income−31−21−66−66−12−28
Interest expense424984
Income tax—0000—
Net income−35−24−67−77−18−31
Diluted EPS−$0.65−$0.36−$0.74−$7.39−$1.68−$1.88
Diluted shares (average)5m7m9m10m11m17m
EBITDA−31−21−65−66−12−28

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SCLX vs VRCAJAGX vs VRCASBFM vs VRCA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Verrica Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Verrica Pharmaceuticals Inc.